Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer BRCA 1. 1 BRCA 1. 1 Breast cancer BRCA 1. 1 gBRCA 1. 1 Pancreatic cancer gBRCA 1. 1 Prostate cancer 1. 1 BRCA BRCA 1. 1 Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA [see Dosage and Administration (2. 1) ] Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: BRCA Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2. 1) Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA [see Error! Hyperlink reference not valid. ] Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA [ Dosage and Administration (2. 1) Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA [see Dosage and Administration (2. 1) Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA [see Dosage and Administration (2. 1) Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2. 1) Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA BRCAm [see Error! Hyperlink reference not valid.

Indication: Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer: 1. 1 AIDS-related Kaposi's Sarcoma: 1. 2 Multiple Myeloma: 1. 3 Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. Doxorubicin hydrochloride liposome injection is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

Indication: Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer: 1. 1 AIDS-related Kaposi's Sarcoma: 1. 2 Multiple Myeloma: 1. 3 Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. Doxorubicin hydrochloride liposome injection is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.